ArticleLeukemia2018
First-in-class oral small molecule inhibitor of the tyrosine kinase ROR1 (KAN0439834) induced significant apoptosis of chronic lymphocytic leukemia cells.
Open access · hybridAbstract read
In one paragraph
Article in Leukemia, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 51 citations in OpenAlex.
- Neoantigenic receptor ROR1 promotes cell growth through diverse and complementary mechanisms.Leukemia · 2026Article
- Cell surface oncofetal antigens in prostate cancer: therapeutic potential and radioligand targeting.EJNMMI research · 2026Review
- ROR1 protein: a pseudokinase at the crossroads of cancer progression and therapy.Molecular biology reports · 2026Review
- Novel Para-Phenylenediamine-Based Derivatives as Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) Inhibitors: An In Vitro Preliminary Characterization.ChemMedChem · 2025Article
- The Multi-Kinase Inhibitor GZD824 (Olverembatinib) Shows Pre-Clinical Efficacy in Endometrial Cancer.Cancer medicine · 2025Article
- Insights into genetic aberrations and signalling pathway interactions in chronic lymphocytic leukemia: from pathogenesis to treatment strategies.Biomarker research · 2024Review
- Unlocking the potential: advancements and future horizons in ROR1-targeted cancer therapies.Science China. Life sciences · 2024Review
- Therapeutic advances in the targeting of ROR1 in hematological cancers.Cell death discovery · 2024Review
- Pentagalloyl Glucose (PGG) Exhibits Anti-Cancer Activity against Aggressive Prostate Cancer by Modulating the ROR1 Mediated AKT-GSK3β Pathway.International journal of molecular sciences · 2024Article
- Receptor tyrosine kinase-like orphan receptor 1: A novel antitumor target in gastrointestinal cancers.World journal of clinical oncology · 2024Review
- A Small Molecule Targeting the Intracellular Tyrosine Kinase Domain of ROR1 (KAN0441571C) Induced Significant Apoptosis of Non-Small Cell Lung Cancer (NSCLC) Cells.Pharmaceutics · 2023Article
- A ROR1 Small Molecule Inhibitor (KAN0441571C) Induced Significant Apoptosis of Mantle Cell Lymphoma (MCL) Cells.Pharmaceutics · 2022Article
- ROR1: an orphan becomes apparent.Blood · 2022Review
- ROR1 and ROR2 expression in pancreatic cancer.BMC cancer · 2021Article
- The ROR1 antibody-drug conjugate huXBR1-402-G5-PNU effectively targets ROR1+ leukemia.Blood advances · 2021Article
- A ROR1 small molecule inhibitor (KAN0441571C) induced significant apoptosis of ibrutinib-resistant ROR1EJHaem · 2021Article
- Predicting ROR1/BCL2 combination targeted therapy of small cell carcinoma of the lung.Cell death & disease · 2021Article
- Conditional Ror1 knockout reveals crucial involvement in lung adenocarcinoma development and identifies novel HIF-1α regulator.Cancer science · 2021Article
- Inhibition of heat shock protein 90 destabilizes receptor tyrosine kinase ROR1 in lung adenocarcinoma.Cancer science · 2021Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 2 institutions in 2 countries.
M Hojjat-FarsangiDepartment of Oncology-Pathology, Immune and Gene Therapy Lab, CancerCenterKarolinska (CCK), Karolinska University Hospital Solna and Karolinska Institute, Stockholm, Sweden.ORCID http://orcid.org/0000-0002-0589-5523
A H DaneshmaneshDepartment of Oncology-Pathology, Immune and Gene Therapy Lab, CancerCenterKarolinska (CCK), Karolinska University Hospital Solna and Karolinska Institute, Stockholm, Sweden.
A S KhanDepartment of Oncology-Pathology, Immune and Gene Therapy Lab, CancerCenterKarolinska (CCK), Karolinska University Hospital Solna and Karolinska Institute, Stockholm, Sweden.
J ShetyeDepartment of Oncology-Pathology, Immune and Gene Therapy Lab, CancerCenterKarolinska (CCK), Karolinska University Hospital Solna and Karolinska Institute, Stockholm, Sweden.
F MozaffariDepartment of Oncology-Pathology, Immune and Gene Therapy Lab, CancerCenterKarolinska (CCK), Karolinska University Hospital Solna and Karolinska Institute, Stockholm, Sweden.
P KharazihaDepartment of Oncology-Pathology, Immune and Gene Therapy Lab, CancerCenterKarolinska (CCK), Karolinska University Hospital Solna and Karolinska Institute, Stockholm, Sweden.
L-S RathjeDepartment of Oncology-Pathology, Immune and Gene Therapy Lab, CancerCenterKarolinska (CCK), Karolinska University Hospital Solna and Karolinska Institute, Stockholm, Sweden.
P KokhaeiDepartment of Oncology-Pathology, Immune and Gene Therapy Lab, CancerCenterKarolinska (CCK), Karolinska University Hospital Solna and Karolinska Institute, Stockholm, Sweden.
L HanssonDepartment of Oncology-Pathology, Immune and Gene Therapy Lab, CancerCenterKarolinska (CCK), Karolinska University Hospital Solna and Karolinska Institute, Stockholm, Sweden.
J VågbergKancera AB, Solna, Sweden.
S ByströmKancera AB, Solna, Sweden.
E OlssonKancera AB, Solna, Sweden.
C LöfbergKancera AB, Solna, Sweden.
C NorströmKancera AB, Solna, Sweden.
J SchultzKancera AB, Solna, Sweden.
M NorinKancera AB, Solna, Sweden.
T OlinKancera AB, Solna, Sweden.
A ÖsterborgDepartment of Oncology-Pathology, Immune and Gene Therapy Lab, CancerCenterKarolinska (CCK), Karolinska University Hospital Solna and Karolinska Institute, Stockholm, Sweden.
H MellstedtDepartment of Oncology-Pathology, Immune and Gene Therapy Lab, CancerCenterKarolinska (CCK), Karolinska University Hospital Solna and Karolinska Institute, Stockholm, Sweden. hakan.mellstedt@sll.se.
A MoshfeghDepartment of Oncology-Pathology, Immune and Gene Therapy Lab, CancerCenterKarolinska (CCK), Karolinska University Hospital Solna and Karolinska Institute, Stockholm, Sweden.
Karolinska University Hospital · SEKancera (Sweden) · SE
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
ApoptosisCell Line, TumorHumansLeukemia, Lymphocytic, Chronic, B-CellPrognosisReceptor Tyrosine Kinase-like Orphan ReceptorsSignal TransductionSmall Molecule LibrariesReceptor Tyrosine Kinase-like Orphan ReceptorsROR1 protein, humanSmall Molecule Libraries
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.